FOLD logo

Amicus Therapeutics, Inc. (FOLD) EBIT

Annual EBIT:

$20.84M+$120.79M(+120.85%)
December 31, 2024

Summary

  • As of today, FOLD annual earnings before interest & taxes is $20.84 million, with the most recent change of +$120.79 million (+120.85%) on December 31, 2024.
  • During the last 3 years, FOLD annual EBIT has risen by +$229.93 million (+109.97%).
  • FOLD annual EBIT is now at all-time high.

Performance

FOLD EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherFOLDincome statement metrics

Quarterly EBIT:

$34.27M+$42.04M(+540.93%)
September 30, 2025

Summary

  • As of today, FOLD quarterly earnings before interest & taxes is $34.27 million, with the most recent change of +$42.04 million (+540.93%) on September 30, 2025.
  • Over the past year, FOLD quarterly EBIT has increased by +$9.47 million (+38.17%).
  • FOLD quarterly EBIT is now -0.57% below its all-time high of $34.46 million, reached on December 31, 2009.

Performance

FOLD Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherFOLDincome statement metrics

TTM EBIT:

$34.52M+$9.47M(+37.79%)
September 30, 2025

Summary

  • As of today, FOLD TTM earnings before interest & taxes is $34.52 million, with the most recent change of +$9.47 million (+37.79%) on September 30, 2025.
  • Over the past year, FOLD TTM EBIT has increased by +$20.11 million (+139.68%).
  • FOLD TTM EBIT is now -27.77% below its all-time high of $47.79 million, reached on March 31, 2025.

Performance

FOLD TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherFOLDincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

FOLD EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+120.8%+38.2%+139.7%
3Y3 Years+110.0%+203.0%+114.7%
5Y5 Years+106.2%+166.3%+112.9%

FOLD EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+110.0%at high+184.1%-27.8%+114.7%
5Y5-Yearat high+106.2%at high+148.7%-27.8%+112.9%
All-TimeAll-Timeat high+104.8%-0.6%+122.1%-27.8%+109.1%

FOLD EBIT History

DateAnnualQuarterlyTTM
Sep 2025
-
$34.27M(+540.9%)
$34.52M(+37.8%)
Jun 2025
-
-$7.77M(+2.3%)
$25.05M(-47.6%)
Mar 2025
-
-$7.95M(-149.8%)
$47.79M(+40.3%)
Dec 2024
$20.84M(+120.9%)
$15.97M(-35.6%)
$34.06M(+136.5%)
Sep 2024
-
$24.80M(+65.7%)
$14.40M(+156.6%)
Jun 2024
-
$14.97M(+169.0%)
-$25.43M(+56.0%)
Mar 2024
-
-$21.68M(-487.1%)
-$57.78M(+21.4%)
Dec 2023
-$99.95M(+51.2%)
-$3.69M(+75.4%)
-$73.49M(+33.5%)
Sep 2023
-
-$15.03M(+13.6%)
-$110.55M(+14.2%)
Jun 2023
-
-$17.39M(+53.5%)
-$128.79M(+25.1%)
Mar 2023
-
-$37.38M(+8.2%)
-$171.90M(+15.9%)
Dec 2022
-$204.92M(+2.0%)
-$40.74M(-22.5%)
-$204.43M(+12.7%)
Sep 2022
-
-$33.27M(+45.0%)
-$234.09M(+2.4%)
Jun 2022
-
-$60.50M(+13.5%)
-$239.93M(-10.4%)
Mar 2022
-
-$69.91M(+0.7%)
-$217.25M(-8.7%)
Dec 2021
-$209.08M(+17.0%)
-$70.41M(-80.0%)
-$199.92M(-3.1%)
Sep 2021
-
-$39.11M(-3.4%)
-$193.88M(+6.1%)
Jun 2021
-
-$37.81M(+28.1%)
-$206.50M(+5.8%)
Mar 2021
-
-$52.58M(+18.3%)
-$219.31M(+10.1%)
Dec 2020
-$251.83M(+25.3%)
-$64.37M(-24.4%)
-$243.85M(+9.0%)
Sep 2020
-
-$51.73M(-2.2%)
-$267.86M(+1.8%)
Jun 2020
-
-$50.63M(+34.4%)
-$272.65M(+8.5%)
Mar 2020
-
-$77.13M(+12.7%)
-$297.97M(+0.9%)
Dec 2019
-$337.04M(-3.2%)
-$88.38M(-56.4%)
-$300.74M(-6.9%)
Sep 2019
-
-$56.52M(+25.6%)
-$281.25M(+25.9%)
Jun 2019
-
-$75.95M(+4.9%)
-$379.61M(-8.4%)
Mar 2019
-
-$79.90M(-16.0%)
-$350.29M(-7.6%)
Dec 2018
-$326.69M(+24.4%)
-$68.88M(+55.5%)
-$325.48M(-1.7%)
Sep 2018
-
-$154.88M(-232.1%)
-$319.97M(-46.0%)
Jun 2018
-
-$46.63M(+15.3%)
-$219.15M(-0.3%)
Mar 2018
-
-$55.08M(+13.1%)
-$218.53M(-3.6%)
Dec 2017
-$431.88M(-117.7%)
-$63.38M(-17.2%)
-$210.88M(-7.9%)
Sep 2017
-
-$54.05M(-17.5%)
-$195.38M(-2.6%)
Jun 2017
-
-$46.01M(+3.0%)
-$190.36M(-4.2%)
Mar 2017
-
-$47.44M(+0.9%)
-$182.70M(-4.4%)
Dec 2016
-$198.38M(-52.0%)
-$47.88M(+2.4%)
-$175.06M(-4.7%)
Sep 2016
-
-$49.04M(-27.9%)
-$167.28M(-9.9%)
Jun 2016
-
-$38.35M(+3.6%)
-$152.18M(-8.9%)
Mar 2016
-
-$39.80M(+0.7%)
-$139.70M(-13.6%)
Dec 2015
-$130.54M
-$40.09M(-18.1%)
-$122.94M(-17.8%)
Sep 2015
-
-$33.94M(-31.2%)
-$104.34M(-18.8%)
Jun 2015
-
-$25.86M(-12.2%)
-$87.80M(-14.6%)
DateAnnualQuarterlyTTM
Mar 2015
-
-$23.05M(-7.3%)
-$76.59M(-11.5%)
Dec 2014
-$68.56M(-8.6%)
-$21.49M(-23.5%)
-$68.66M(-13.5%)
Sep 2014
-
-$17.40M(-18.8%)
-$60.48M(-3.9%)
Jun 2014
-
-$14.65M(+3.1%)
-$58.21M(+2.3%)
Mar 2014
-
-$15.12M(-13.7%)
-$59.57M(+3.4%)
Dec 2013
-$63.10M(-21.5%)
-$13.30M(+12.1%)
-$61.69M(+3.5%)
Sep 2013
-
-$15.13M(+5.4%)
-$63.91M(+2.7%)
Jun 2013
-
-$16.00M(+7.2%)
-$65.69M(-11.3%)
Mar 2013
-
-$17.25M(-11.1%)
-$59.04M(-12.4%)
Dec 2012
-$51.94M(-8.5%)
-$15.52M(+8.2%)
-$52.53M(-5.0%)
Sep 2012
-
-$16.92M(-81.0%)
-$50.04M(-8.3%)
Jun 2012
-
-$9.35M(+13.0%)
-$46.20M(+10.4%)
Mar 2012
-
-$10.74M(+17.5%)
-$51.58M(-1.5%)
Dec 2011
-$47.89M(+14.2%)
-$13.03M(+0.4%)
-$50.83M(+6.5%)
Sep 2011
-
-$13.08M(+11.2%)
-$54.34M(+0.3%)
Jun 2011
-
-$14.72M(-47.3%)
-$54.52M(-3.9%)
Mar 2011
-
-$10.00M(+39.5%)
-$52.49M(+6.0%)
Dec 2010
-$55.81M(-787.5%)
-$16.54M(-24.7%)
-$55.84M(-1054.4%)
Sep 2010
-
-$13.27M(-4.6%)
-$4.84M(+4.1%)
Jun 2010
-
-$12.69M(+5.0%)
-$5.05M(+18.8%)
Mar 2010
-
-$13.35M(-138.7%)
-$6.21M(-6.5%)
Dec 2009
-$6.29M(+83.9%)
$34.46M(+355.8%)
-$5.83M(+89.4%)
Sep 2009
-
-$13.47M(+2.7%)
-$55.17M(-8.2%)
Jun 2009
-
-$13.85M(-6.8%)
-$51.00M(-7.1%)
Mar 2009
-
-$12.97M(+12.8%)
-$47.64M(-8.4%)
Dec 2008
-$39.14M(+14.6%)
-$14.88M(-60.0%)
-$43.96M(-3.3%)
Sep 2008
-
-$9.30M(+11.4%)
-$42.56M(+5.6%)
Jun 2008
-
-$10.49M(-13.0%)
-$45.07M(-0.5%)
Mar 2008
-
-$9.29M(+31.1%)
-$44.86M(+2.1%)
Dec 2007
-$45.80M(+2.2%)
-$13.48M(-14.2%)
-$45.81M(-41.7%)
Sep 2007
-
-$11.81M(-14.8%)
-$32.32M(-57.5%)
Jun 2007
-
-$10.28M(-0.5%)
-$20.52M(-100.5%)
Mar 2007
-
-$10.23M(>-9900.0%)
-$10.23M(>-9900.0%)
Dec 2006
-$46.86M(-124.9%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2006
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2006
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2006
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2005
-$20.83M(-136.5%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2005
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2005
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2005
-
$0.00
$0.00
Dec 2004
-$8.81M(-33.4%)
-
-
Dec 2003
-$6.60M
-
-

FAQ

  • What is Amicus Therapeutics, Inc. annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for Amicus Therapeutics, Inc.?
  • What is Amicus Therapeutics, Inc. annual EBIT year-on-year change?
  • What is Amicus Therapeutics, Inc. quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for Amicus Therapeutics, Inc.?
  • What is Amicus Therapeutics, Inc. quarterly EBIT year-on-year change?
  • What is Amicus Therapeutics, Inc. TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for Amicus Therapeutics, Inc.?
  • What is Amicus Therapeutics, Inc. TTM EBIT year-on-year change?

What is Amicus Therapeutics, Inc. annual earnings before interest & taxes?

The current annual EBIT of FOLD is $20.84M

What is the all-time high annual EBIT for Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. all-time high annual earnings before interest & taxes is $20.84M

What is Amicus Therapeutics, Inc. annual EBIT year-on-year change?

Over the past year, FOLD annual earnings before interest & taxes has changed by +$120.79M (+120.85%)

What is Amicus Therapeutics, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of FOLD is $34.27M

What is the all-time high quarterly EBIT for Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. all-time high quarterly earnings before interest & taxes is $34.46M

What is Amicus Therapeutics, Inc. quarterly EBIT year-on-year change?

Over the past year, FOLD quarterly earnings before interest & taxes has changed by +$9.47M (+38.17%)

What is Amicus Therapeutics, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of FOLD is $34.52M

What is the all-time high TTM EBIT for Amicus Therapeutics, Inc.?

Amicus Therapeutics, Inc. all-time high TTM earnings before interest & taxes is $47.79M

What is Amicus Therapeutics, Inc. TTM EBIT year-on-year change?

Over the past year, FOLD TTM earnings before interest & taxes has changed by +$20.11M (+139.68%)
On this page